<DOC>
	<DOCNO>NCT02251964</DOCNO>
	<brief_summary>This project address rare immune mediate inflammatory disease ( IMIDs ) involve lung , i.e . interstitial pneumonitis ( IP ) . The main objective study assess effect rituximab ( RTX ) rescue therapy progressive IMID-IP patient . The primary study parameter pulmonary function . The secondary objective explore application imaging radiolabeled RTX early predictor efficacy RTX , study effect RTX treatment quality life , elucidate pathophysiology IMID-IP analyze biochemical marker .</brief_summary>
	<brief_title>Rituximab Interstitial Pneumonitis</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>In order eligible participate study , subject must meet following criterion : Age 18 70 year No previous therapy rituximab At least 2 pulmonary function test within past 6 month Diagnosis coexist IMID severe / progressive IP characterize 3 follow item : Respiratory symptom consistent interstitial lung disease Diagnosis usual interstitial pneumonia ( UIP ) , nonspecific interstitial pneumonia ( NSIP ) , organize pneumonia ( OP ) mix form UIP / NSIP / OP either follow : Open videoassisted thoracic surgery ( VATS ) lung biopsy show definite probable UIP / NSIP / OP High Resolution Computer Tomography ( HRCT ) scan show definite probable UIP/NSIP/OP/mixed Forced Vital Capacity ( FVC ) &lt; 50 % predict and/or diffusing capacity lung carbon monoxide ( DLCO ) &lt; 40 % predict worsen lung function demonstrate one follow within past year : &gt; 10 % decrease FVC &gt; 15 % decrease DLCO Therapy resistance 1st ( corticosteroid ) 2nd line therapy ( cyclophosphamide azathioprine ) A potential subject meet follow criterion exclude participation study : Residual volume &gt; 120 % predict screen DLCO &lt; 25 % predict value screen + rest Oxygen Saturation ( SAO2 ) without external oxygen &lt; 90 % History unstable deteriorate cardiac neurological disease Pregnancy lactation Hematology low specify limit ( leucocyte ) Positive HIV , hepatitis B C serology Preexisting condition lead life expectancy le 6 month Receipt vaccine , particularly live viral vaccine , within 4 week first rituximab dose Hypersensitivity murine protein NOTE : Fever ( &gt; 37,9 Â°C ) presentation reason delay therapy 1 week Evidence active infection reason postpone rituximab treatment sign active infection Severe renal impairment contraindication rituximab therapy , however , patient ( might ) require dialysis frequently exclude study group</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>IMID</keyword>
	<keyword>Interstitial Pneumonitis</keyword>
	<keyword>rituximab</keyword>
	<keyword>Immuno PET</keyword>
	<keyword>PET/CT</keyword>
</DOC>